| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OSX |
| Uniprot No | O15344 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-667aa |
| 氨基酸序列 | METLESELTC PICLELFEDP LLLPCAHSLC FNCAHRILVS HCATNESVES ITAFQCPTCR HVITLSQRGL DGLKRNVTLQ NIIDRFQKAS VSGPNSPSET RRERAFDANT MTSAEKVLCQ FCDQDPAQDA VKTCVTCEVS YCDECLKATH PNKKPFTGHR LIEPIPDSHI RGLMCLEHED EKVNMYCVTD DQLICALCKL VGRHRDHQVA ALSERYDKLK QNLESNLTNL IKRNTELETL LAKLIQTCQH VEVNASRQEA KLTEECDLLI EIIQQRRQII GTKIKEGKVM RLRKLAQQIA NCKQCIERSA SLISQAEHSL KENDHARFLQ TAKNITERVS MATASSQVLI PEINLNDTFD TFALDFSREK KLLECLDYLT APNPPTIREE LCTASYDTIT VHWTSDDEFS VVSYELQYTI FTGQANVVSL CNSADSWMIV PNIKQNHYTV HGLQSGTKYI FMVKAINQAG SRSSEPGKLK TNSQPFKLDP KSAHRKLKVS HDNLTVERDE SSSKKSHTPE RFTSQGSYGV AGNVFIDSGR HYWEVVISGS TWYAIGLAYK SAPKHEWIGK NSASWALCRC NNNWVVRHNS KEIPIEPAPH LRRVGILLDY DNGSIAFYDA LNSIHLYTFD VAFAQPVCPT FTVWNKCLTI ITGLPIPDHL DCTEQLP |
| 预测分子量 | 75,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于Osterix(OSX/SP7)重组蛋白的相关文献概览，供参考：
---
1. **文献名称**：*"Recombinant Osterix enhances osteogenic differentiation of human mesenchymal stem cells in vitro"*
**作者**：Zhang et al. (2016)
**摘要**：研究通过原核系统表达并纯化OSX重组蛋白，验证其可诱导人间充质干细胞成骨分化，证明其通过激活Runx2通路促进骨形成。
---
2. **文献名称**：*"Structural and functional analysis of the Osterix transcription factor"*
**作者**：Kim et al. (2013)
**摘要**：解析OSX重组蛋白的锌指结构域三维结构，揭示其与DNA结合的关键位点，为调控骨发育的分子机制提供结构基础。
---
3. **文献名称**：*"Expression and purification of bioactive Osterix in a mammalian cell system for bone regeneration studies"*
**作者**：Lee & Park (2018)
**摘要**：利用哺乳动物细胞(HEK293)表达OSX重组蛋白，优化纯化流程并证明其生物活性，应用于3D骨组织工程模型中的骨再生实验。
---
如需更具体的文献或领域细分(如疾病治疗、信号通路等)，请补充说明以便进一步筛选!
OSX (Osterix), also known as Sp7. is a zinc finger-containing transcription factor essential for osteoblast differentiation and bone formation. Discovered in 2002. it functions as a master regulator of osteogenesis, activating genes critical for extracellular matrix (ECM) mineralization, including those encoding type I collagen, osteocalcin, and alkaline phosphatase. Unlike Runx2. another key osteogenic factor, OSX operates downstream in the differentiation cascade, specifically committing mesenchymal stem cells to the osteoblast lineage. Its absence in knockout models results in complete lack of bone formation, highlighting its non-redundant role in skeletal development.
Recombinant OSX protein is produced using genetic engineering techniques, typically expressed in bacterial (e.g., E. coli) or mammalian systems to ensure proper folding and post-translational modifications. This engineered protein retains the DNA-binding capacity of native OSX, enabling researchers to study its molecular interactions, signaling pathways, and regulatory mechanisms in controlled experimental settings. Purification processes often incorporate affinity tags (e.g., His-tag) for efficient isolation while maintaining biological activity.
In research, recombinant OSX facilitates investigations into bone metabolism disorders, fracture healing, and skeletal regeneration strategies. It serves as a tool for modulating osteogenic differentiation in cell cultures and organoid models. Therapeutic applications are emerging in tissue engineering, particularly in combination with biomaterial scaffolds to enhance bone repair. Additionally, it aids in drug discovery for osteoporosis and genetic bone diseases by enabling high-throughput screening of compounds affecting osteoblast function. Recent advances in CRISPR-Cas9 and 3D cell culture systems have further expanded its utility in modeling bone pathologies and testing gene therapies. Ongoing studies explore its potential in dental tissue regeneration and metastatic bone disease management.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
